Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

NCT04571372 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2020-11-30

No results posted yet for this study

Summary

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

Conditions

  • Severe Aortic Stenosis or Severe Aortic Regurgitation

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-23
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04571372 on ClinicalTrials.gov